This process begins with evaluating characteristic symptoms- such as chest pain, arrhythmias, or heart failure manifestations-alongside elevated serum biomarkers, including cardiac troponin I/T (cTnI/cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). This evidence concerns the gene TNNI3 and cardiac arrhythmia.